J Bone Metab.  2016 Feb;23(1):16-22. 10.11005/jbm.2016.23.1.16.

Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry

• Almansouri AY
• Abdulfatah ME
• Baaqil OH
• Bakheet AA
• Turki SA
• Kotb MM
• Althubaiti A
• Almaghrabi MM
• Althubaiti AM
• Madani BM
• Jawad AS

• KMID: 2156282
• DOI: http://doi.org/10.11005/jbm.2016.23.1.16

Abstract

BACKGROUND
The aim of the study was to compare serum sclerostin levels in human im-munodeficiency virus (HIV)-infected patients and healthy controls, and to evaluate their relationship with bone turnover markers (BTM) and bone mineral density (BMD).
METHODS
We prospectively studied 33 HIV treatment-naive patients and 63 healthy individuals; matched for age and sex. Serum sclerostin levels, BTM, BMD were measured. Viral load and cluster of differentiation 4 (CD4) levels were also assessed in HIV-infected patients.
RESULTS
The mean+/-standard deviation (SD) age of sample was 37.6+/-10.3 years (range, 19 to 59 years). Of the 96 subjects, 58 (60.4%) were male and 38 (39.6%) were female. Infection with HIV is associated with significant reduction in serum sclerostin levels (HIV-infected: 39.4+/-28.3 vs. non HIV: 76.6+/-15.7 pmol/L; P<0.001) and a decrease in BMD at femoral neck and lumbar spine compared to healthy controls. Sclerostin however was not correlated with BMD and was not related to age, generally a strong correlation. There were no significant correlations between sclerostin and BTM (P>0.05).
CONCLUSIONS
These findings suggest that untreated HIV and the resulting immune deficiency and/or systemic inflammation could be an important regulator of serum sclerostin in this population.

Keyword

Glycoproteins; HIV; Osteoporosis; Saudi Arabia

MeSH Terms

Bone Density
Densitometry*
Female
Femur Neck
Glycoproteins
HIV*
Humans
Humans*
Inflammation
Male
Osteoporosis
Prospective Studies
Saudi Arabia
Spine
Viral Load
Glycoproteins

Figure

• 

  Fig. 1 This figure is a Box and Whisker's Plot that shows the mean value (middle line) of sclerostin level of groups, 75th percentile (darker shade), 25th percentile (lighter shade) and lastly the error bars of the min and max (N for human immunodeficiency virus-infected=33, N for healthy control=63). HIV, human immunodeficiency virus.

Reference

1. Yong MK, Elliott JH, Woolley IJ, et al. Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr. 2011; 57:205–210.

2. Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS. 2009; 23:1297–1310.

3. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008; 22:395–402.

4. Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007; 21:617–623.

5. Fausto A, Bongiovanni M, Cicconi P, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006; 38:893–897.

6. Ardawi MS, Rouzi AA, Qari MH. Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab. 2012; 97:3691–3699.

7. You L, Temiyasathit S, Lee P, et al. Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone. 2008; 42:172–179.

8. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011; 377:1276–1287.

9. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280:19883–19887.

10. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68:577–589.

11. Horowitz MC, Fretz JA. Sclerostin: a new mediator of crosstalk between the skeletal and immune systems. J Bone Miner Res. 2012; 27:1448–1450.

12. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007; 7:292–304.

13. Cain CJ, Rueda R, McLelland B, et al. Absence of sclerostin adversely affects B-cell survival. J Bone Miner Res. 2012; 27:1451–1461.

14. Bellido T, Saini V, Pajevic PD. Effects of PTH on osteocyte function. Bone. 2013; 54:250–257.

15. Mirza FS, Padhi ID, Raisz LG, et al. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010; 95:1991–1997.

16. Robling AG, Niziolek PJ, Baldridge LA, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008; 283:5866–5875.

17. Frings-Meuthen P, Boehme G, Liphardt AM, et al. Sclerostin and DKK1 levels during 14 and 21 days of bed rest in healthy young men. J Musculoskelet Neuronal Interact. 2013; 13:45–52.

18. Ardawi MS, Al-Kadi HA, Rouzi AA, et al. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011; 26:2812–2822.

19. Hui SL, Gao S, Zhou XH, et al. Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res. 1997; 12:1463–1470.

20. Lu Y, Fuerst T, Hui S, et al. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int. 2001; 12:438–444.

21. Damilakis J, Guglielmi G. Quality assurance and dosimetry in bone densitometry. Radiol Clin North Am. 2010; 48:629–640.

22. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1–129.

23. Amrein K, Amrein S, Drexler C, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012; 97:148–154.

24. Morse LR, Sudhakar S, Danilack V, et al. Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res. 2012; 27:352–359.

25. Morse LR, Sudhakar S, Lazzari AA, et al. Sclerostin: a candidate biomarker of SCI-induced osteoporosis. Osteoporos Int. 2013; 24:961–968.

26. Madani TA, Al-Mazrou YY, Al-Jeffri MH, et al. Epidemiology of the human immunodeficiency virus in Saudi Arabia; 18-year surveillance results and prevention from an Islamic perspective. BMC Infect Dis. 2004; 4:25.

27. Mazroa MA, Kabbash IA, Felemban SM, et al. HIV case notification rates in the Kingdom of Saudi Arabia over the past decade (2000-2009). PLoS One. 2012; 7:e45919.

28. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature. 2001; 410:980–987.

29. World Health Organization. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance. Geneva: World Health Organization;2005.

30. Garnero P, Sornay-Rendu E, Munoz F, et al. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013; 24:489–494.

31. González-Reimers E, López-Prieto J, Pelazas-González R, et al. Serum sclerostin in hepatitis C virus infected patients. J Bone Metab. 2014; 21:69–75.